Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
Clin. transl. oncol. (Print)
; 24(2): 161-192, febrero 2022.
Artigo
em Inglês
| IBECS
| ID: ibc-203425
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Cyclin-dependent kinases (CDKs) play a key regulating role in the cell cycle, which is almost universally altered in cancer, leading to sustained proliferation. Early pan-CDK inhibitors showed poor results in clinical trials for solid malignancies, as the lack of selectivity produced significant toxicity. The production of more selective inhibitors led to significant developments in cancer therapy, as CDK4/6 inhibitors in combination with endocrine therapy changed the landscape of the treatment of hormone-receptor positive (HR +) metastatic breast cancer. Recently, Trilaciclib demonstrated benefits regarding hematological toxicity compared to placebo when administered in combination with chemotherapy in small cell lung cancer. Newer agents, such as SY-5609, a selective CDK7 inhibitor, have also shown promising results in early clinical trials. In this paper, we review the data from clinical trials of CDK inhibitors in solid tumors, either as a monotherapy or in combination with other agents, with an emphasis on novel agents and potential new indications for this drug class.
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Ciclinas
/
Inibidores de Proteínas Quinases
/
Ciências da Saúde
/
Pontos de Checagem do Ciclo Celular
/
Antineoplásicos
Limite:
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2022
Tipo de documento:
Artigo
Instituição/País de afiliação:
Athens School of Medicine/Greece